Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2011

View Archived Issues

Anti-HIV antibody response at mucosal sites protects monkeys against infection

Roskamp Institute obtains IRB approval for study of RCP-006 in humans

IQ Therapeutics begins phase I trial of IQ-DAA for anthrax

Expression of bone morphogenetic protein 7 predicts clinical outcome in gastric cancer

Autoantibodies against tyrosine 3-monooxygenase are increased in patients with generalized vitiligo

Ganetespib is active in NSCLC and set to enter phase IIb/III trial in combination with docetaxel

GS-7340 is more effective than TDF in reducing HIV-1 RNA in patients

Pharmacyclics suspends development of tyrosine-protein kinase BTK inhibitor PCI-45292

Merck KGaA discloses novel protein kinase inhibitors

Merz presents new modulators of metabotropic glutamate mGlu5 receptor

Bavarian Nordic joins Danish research project to develop anticancer vaccines

New metal chelators presented by FerroKin

New glucocorticoid receptor ligands patented by Karo Bio and Zydus-Cadila

Targacept and GSK terminate strategic alliance

FDA accepts for review Lundbeck's NDA for clobazam in Lennox-Gastaut syndrome

GlaxoSmithKline submits MAA in Europe for Nimenrix meningitis vaccine

Novartis synthesizes new inhibitors of hepatocyte growth factor receptor

DURATION-6 trial of diabetes therapy Bydureon misses primary endpoint

Eisai receives FDA approval for Banzel oral suspension

European Commission grants orphan drug status to ThermoDox in primary liver cancer

Cell Therapeutics meets with FDA to appeal decision on pixantrone

DiaMedica's DM-204 reduces hypertension in animal models

Ceplene/IL-2 combination improves survival of patients with AML of monocyte origin

Allos and FDA reach SPA agreement for phase III trial of Folotyn in peripheral T-cell lymphoma

Cellceutix reports new data on anticancer drug Kevetrin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...